253 related articles for article (PubMed ID: 24569669)
1. Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis.
Parikh R; Dalwadi S; Aboti P; Patel L
J Antibiot (Tokyo); 2014 May; 67(5):387-94. PubMed ID: 24569669
[TBL] [Abstract][Full Text] [Related]
2. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats.
Parikh R; Patel L; Dalwadi S
Drug Deliv; 2014 Sep; 21(6):406-11. PubMed ID: 24215141
[TBL] [Abstract][Full Text] [Related]
3. Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages.
Zhou H; Zhang Y; Biggs DL; Manning MC; Randolph TW; Christians U; Hybertson BM; Ng KY
J Control Release; 2005 Oct; 107(2):288-99. PubMed ID: 16009444
[TBL] [Abstract][Full Text] [Related]
4. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.
Sharma R; Saxena D; Dwivedi AK; Misra A
Pharm Res; 2001 Oct; 18(10):1405-10. PubMed ID: 11697465
[TBL] [Abstract][Full Text] [Related]
5. Inhalable microparticles containing large payload of anti-tuberculosis drugs.
Muttil P; Kaur J; Kumar K; Yadav AB; Sharma R; Misra A
Eur J Pharm Sci; 2007 Oct; 32(2):140-50. PubMed ID: 17681458
[TBL] [Abstract][Full Text] [Related]
6. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.
Dutt M; Khuller GK
Int J Antimicrob Agents; 2001 Feb; 17(2):115-22. PubMed ID: 11165115
[TBL] [Abstract][Full Text] [Related]
7. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
8. Inhalable Antitubercular Therapy Mediated by Locust Bean Gum Microparticles.
Alves AD; Cavaco JS; Guerreiro F; Lourenço JP; Rosa da Costa AM; Grenha A
Molecules; 2016 May; 21(6):. PubMed ID: 27240337
[TBL] [Abstract][Full Text] [Related]
9. Alginate microspheres of isoniazid for oral sustained drug delivery.
Rastogi R; Sultana Y; Aqil M; Ali A; Kumar S; Chuttani K; Mishra AK
Int J Pharm; 2007 Apr; 334(1-2):71-7. PubMed ID: 17113732
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Delivery of Isoniazid in Nanogel-Loaded Chitosan Hybrid Microparticles for Inhalation.
Omar SM; Maziad NA; El-Tantawy NM
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):78-87. PubMed ID: 30526251
[TBL] [Abstract][Full Text] [Related]
11. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis.
Sharma A; Vaghasiya K; Ray E; Gupta P; Kumar Singh A; Datta Gupta U; Kumar Verma R
Int J Pharm; 2019 Mar; 558():231-241. PubMed ID: 30630076
[TBL] [Abstract][Full Text] [Related]
12. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
13. Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis.
Manca ML; Cassano R; Valenti D; Trombino S; Ferrarelli T; Picci N; Fadda AM; Manconi M
J Pharm Pharmacol; 2013 Sep; 65(9):1302-11. PubMed ID: 23927468
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.
Rojanarat W; Changsan N; Tawithong E; Pinsuwan S; Chan HK; Srichana T
Int J Mol Sci; 2011; 12(7):4414-34. PubMed ID: 21845086
[TBL] [Abstract][Full Text] [Related]
15. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.
Verma RK; Kaur J; Kumar K; Yadav AB; Misra A
Antimicrob Agents Chemother; 2008 Sep; 52(9):3195-201. PubMed ID: 18591268
[TBL] [Abstract][Full Text] [Related]
16. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
17. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
18. Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.
Fernández-Paz C; Fernández-Paz E; Salcedo-Abraira P; Rojas S; Barrios-Esteban S; Csaba N; Horcajada P; Remuñán-López C
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770817
[TBL] [Abstract][Full Text] [Related]
19. Microparticles prepared with 50-190kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid.
Oliveira PM; Matos BN; Pereira PAT; Gratieri T; Faccioli LH; Cunha-Filho MSS; Gelfuso GM
Carbohydr Polym; 2017 Oct; 174():421-431. PubMed ID: 28821088
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Delivery of Anti-Tubercular Drugs Using Ligand Anchored pH Sensitive Liposomes for the Treatment of Pulmonary Tuberculosis.
Bhardwaj A; Grobler A; Rath G; Goyal AK; Jain AK; Mehta A
Curr Drug Deliv; 2016; 13(6):909-22. PubMed ID: 26718489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
